An Open Label, Multi-center, Phase Ib/II Clinical Study of AK109 Combined With AK104 to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cadonilimab (Primary) ; Pulocimab (Primary)
Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Akeso Biopharma

23 Apr 2024 Planned End Date changed from 20 Mar 2024 to 1 Dec 2024.
23 Apr 2024 Planned primary completion date changed from 22 Feb 2023 to 1 Dec 2024.
17 Oct 2022 Planned End Date changed from 20 Oct 2023 to 20 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com